We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
There’s going to be a torrent of activity and information this week, the busiest of Q4 Earnings Season so far, but this morning we’re fairly quiet. Because Big Tech reports earnings later this week — Apple (AAPL - Free Report) and Tesla (TSLA - Free Report) among the companies putting out quarterly results — we see the Nasdaq +120 points an hour before the opening bell. However, the Dow currently looks prepped to open down 120 points, while the S&P 500 is flat.
Aside from earnings releases and a subsequent progress report on how Big Tech performed in calendar Q4, we also see a smorgasbord of economic reads lined up for the week: Case Shiller home prices for November, Consumer Confidence for January, Durable Goods for December, Q4 GDP, Advance Trade in Goods, New Home Sales, Personal Income and Consumer Spending and a new meeting of the FOMC and Jay Powell presser are all on tap. Again, however — not today. Today we’re quiet on that front, as well.
Moderna (MRNA - Free Report) shares are up more than 5% in Monday’s pre-market on news that its Covid-19 vaccine does show efficacy against newer mutations of the coronavirus. This is particularly good news for those regions hardest hit by the newer, more contagious strains developing from the original Covid-19 strain that first hit American shores roughly one year ago. It’s been more than a week since we last registered 200K new cases in this country, although fatalities from the disease continue at a torrid pace, between 3000-4000 per day in this country.
The good news is it appears as if the holiday season spike in new cases, as a result of people traveling to see loved ones late last month, is passing. Not only cases and deaths but hospitalizations have come down in recent days, which is obviously a good sign. As schools, exercise gyms and restaurants — all in various states of limited capacity — begin to open in the state of Illinois and elsewhere, we will keep a close eye on these daily results in case they turn back in the wrong direction.
Ahead of today’s open, Zacks Rank #3 (Hold)-rated paper products manufacturer Kimberly-Clark (KMB - Free Report) beat both top- and bottom-line estimates in its Q4 report. The Irving, TX-based company put up $1.69 per share, 8 cents higher than the Zacks consensus, though slightly below the $1.71 per share reported in the year-ago quarter. The company also beat revenue estimates by 2% to $4.84 billion, ahead of the $4.58 billion a year ago.
Shares of Kimberly-Clark are up 1.3% in today’s pre-market, which remains below the start of 2021, and off pace of the company’s all-time highs posted last August, up near $159 per share. We await updates on earnings estimates from our analysts to see if a rank change is suitable for the company. For more on KMB’s earnings, click here.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Quiet Before the Q4 Earnings Storm
Monday, January 25, 2021
There’s going to be a torrent of activity and information this week, the busiest of Q4 Earnings Season so far, but this morning we’re fairly quiet. Because Big Tech reports earnings later this week — Apple (AAPL - Free Report) and Tesla (TSLA - Free Report) among the companies putting out quarterly results — we see the Nasdaq +120 points an hour before the opening bell. However, the Dow currently looks prepped to open down 120 points, while the S&P 500 is flat.
Aside from earnings releases and a subsequent progress report on how Big Tech performed in calendar Q4, we also see a smorgasbord of economic reads lined up for the week: Case Shiller home prices for November, Consumer Confidence for January, Durable Goods for December, Q4 GDP, Advance Trade in Goods, New Home Sales, Personal Income and Consumer Spending and a new meeting of the FOMC and Jay Powell presser are all on tap. Again, however — not today. Today we’re quiet on that front, as well.
Moderna (MRNA - Free Report) shares are up more than 5% in Monday’s pre-market on news that its Covid-19 vaccine does show efficacy against newer mutations of the coronavirus. This is particularly good news for those regions hardest hit by the newer, more contagious strains developing from the original Covid-19 strain that first hit American shores roughly one year ago. It’s been more than a week since we last registered 200K new cases in this country, although fatalities from the disease continue at a torrid pace, between 3000-4000 per day in this country.
The good news is it appears as if the holiday season spike in new cases, as a result of people traveling to see loved ones late last month, is passing. Not only cases and deaths but hospitalizations have come down in recent days, which is obviously a good sign. As schools, exercise gyms and restaurants — all in various states of limited capacity — begin to open in the state of Illinois and elsewhere, we will keep a close eye on these daily results in case they turn back in the wrong direction.
Ahead of today’s open, Zacks Rank #3 (Hold)-rated paper products manufacturer Kimberly-Clark (KMB - Free Report) beat both top- and bottom-line estimates in its Q4 report. The Irving, TX-based company put up $1.69 per share, 8 cents higher than the Zacks consensus, though slightly below the $1.71 per share reported in the year-ago quarter. The company also beat revenue estimates by 2% to $4.84 billion, ahead of the $4.58 billion a year ago.
Shares of Kimberly-Clark are up 1.3% in today’s pre-market, which remains below the start of 2021, and off pace of the company’s all-time highs posted last August, up near $159 per share. We await updates on earnings estimates from our analysts to see if a rank change is suitable for the company. For more on KMB’s earnings, click here.
Questions or comments about this article and/or its author? Click here>>
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>